081 Results of the survey ithaque: monitoring and therapies for systolic heart failure

Abstract

Electrical therapies by defibrillators (ICD) and resynchronization devices (CRT-D – CRT-P), have demonstrated their benefits on symptoms, morbidity and mortality in selected heart failure patients (HF). The ITHAQUE survey aims to describe the different supports of patients in HF patients with impaired left ventricular (LV) function (LV ejection fraction < 45%) 927 patients treated for HF were seen in outpatient visit with a general cardiologist (75%) or in a tertiary center (25%). A survey of treatments and follow-ups was completed by the physician. 3 groups under optimal treatment, defined by the French Society of Cardiology (SFC) guidelines, have been analyzed: Gr1 – Class 1B (patients with ischemic cardiomyopathy and coronary revascularization, NYHA II and III, LVEF <30%) – Class 2aB (30% Gr2 – Class 2aB (dilated cardiomyopathy, NYHA II and III, LVEF <30%) and class 2bC (30% Gr3 – Class 1B (HF Patients, NYHA III and IV, LVEF <35% and QRS >120 ms) Of the total patients, 79 received an ICD (8.5%), 22 a CRT-D (2.4%) and 76 a CRT-P (8.2%). On the other side, 279 patients eligible according to the recommendations of the SFC did not receive additional treatment with ICD or CRT (30%). Pharmacological treatment associated is mainly composed of IEC (76.5%), Beta-blockers (76.6%), Diuretics (90%), anticoagulants (80%) and Anti-arrhythmic (31%). Rules lifestyle modifications (77.8%) and practice of physical activity (31.2%) are also prescribed, associated or not. Although the specific conditions of therapeutic patient must be taken into account, the ITHAQUE survey did show that the electrical therapies recommended by the SFC for heart failure patients with systolic dysfunction are underused.